A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

Name: A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Published: 2020
License: Public Domain

Kinevant Sciences GmbH · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

coronavirus monoclonal-antibody

covid-19, granulocyte macrophage-colony stimulating factor (gm-csf), immunomodulator, cytokine storm, coronavirus, severe acute respiratory syndrome (sars), lung injury, monoclonal antibody, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

Related documents